The impact of ESG investing is too significant to ignore and with the battle for funds at its peak, the biotech industry needs to be at the forefront of the agenda. With impending mandates, the pressure is firmly on businesses to start thinking about their ESG proposition and how it may positively influence and affect the wider industry.
How can global business leaders deliver on ambitions of growth and reinvention?
An interview with Alistair Kirk, transformation programme expert and member of the UK’s Vaccine Taskforce.
Gil Carrara, U.S. Managing Partner and Healthcare & Life Sciences Regional Leader, discusses new strategic opportunities stemming from the health and wellness sector this year.
Going virtual – how COVID has accelerated a real shift in clinical trial methodology
Gil Carrara, Americas Leader of Boyden’s Healthcare & Life Sciences Practice, looks at how Microsoft and other tech firms are changing the healthcare landscape.
